SDCL EDGE Acquisition Corporation

UK Launches £18.8 Million Initiative to Transform Nuclear Waste into Precision Cancer Therapies

- The UK has announced a £18.8 million investment to develop targeted alpha therapies using lead-212 extracted from recycled nuclear fuel for precision cancer treatment. - The project, co-led by UK National Nuclear Laboratory and Medicines Discovery Catapult, aims to create an "evergreen" supply of radiopharmaceuticals that directly attack cancer cells while sparing healthy tissue. - A tiny amount of processed material equivalent to a single drop of water in an Olympic-sized swimming pool could potentially treat thousands of cancer patients. - The initiative positions the UK to provide these innovative treatments both domestically and globally, targeting previously untreatable cancers with sustainable nuclear waste utilization.